Skip to main content

Advertisement

SpringerLink
Log in

Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3,4)-bisphosphate

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

We evaluated tumor cell growth modulation by bee venom secretory phospholipase A2 (bv-sPLA2) and phosphatidylinositol-(3,4)-bisphosphate as well as potential cooperative effects. In addition, the immunomodulatory impact of tumor cell treatment was examined by monitoring changes in phenotype and function of monocyte-derived dendritic cells (moDCs) cocultured with pretreated tumor cells. Bv-sPLA2 or phosphatidylinositol-(3,4)-bisphosphate alone displayed moderate effects on the proliferation of A498 renal cell carcinoma cells, T-47D breast cancer cells, DU145 prostate cancer cells and BEAS-2B transformed lung cells. However, when bv-sPLA2 was coadministered with phosphatidylinositol-(3,4)-bisphosphate a potent inhibition of [3H] thymidine incorporation into all tested cell lines occurred. This inhibition was due to massive cell lysis that reduced the number of cells with proliferative capacity. Importantly, tumor cell lysates generated with bv-sPLA2 plus phosphatidylinositol-(3,4)-bisphosphate induced maturation of human moDCs demonstrated by enhanced expression of CD83 and improved stimulation in allogeneic mixed leukocyte reactions. Our data demonstrate that bv-sPLA2 and phosphatidylinositol-(3,4)-bisphosphate synergistically generate tumor lysates which enhance the maturation of immunostimulatory human monocyte-derived dendritic cells. Such tumor lysates which represent complex mixtures of tumor antigens and simultaneously display potent adjuvant properties meet all requirements of a tumor vaccine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Andreae S, Buisson S, Triebel F (2003) MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 102:2130–2137

    Article  PubMed  CAS  Google Scholar 

  2. Appel S, Rupf A, Weck MM, Schoor O, Brummendorf TH, Weinschenk T, Grunebach F, Brossart P (2005) Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res 11:1928–1940

    Article  PubMed  CAS  Google Scholar 

  3. Ashagbley A, Samadder P, Bittman R, Erukulla RK, Byun HS, Arthur G (1996) Synthesis of ether-linked analogues of lysophosphatidate and their effect on the proliferation of human epithelial cancer cells in vitro. Anticancer Res 16:1813–1818

    PubMed  CAS  Google Scholar 

  4. Babon A, Almunia C, Boccaccio C, Beaumelle B, Gelb MH, Menez A, Maillere B, Abastado JP, Salcedo M, Gillet D (2005) Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2 as a membrane-binding vector. FEBS Lett 579:1658–1664

    Article  PubMed  CAS  Google Scholar 

  5. Balsinde J, Dennis EA (1997) Function and inhibition of intracellular calcium-independent phospholipase A2. J Biol Chem 272:16069–16072

    Article  PubMed  CAS  Google Scholar 

  6. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252

    Article  PubMed  CAS  Google Scholar 

  7. den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ (2005) Dendritic cells: tools and targets for antitumor vaccination. Expert Rev Vaccines 4:699–710

    Article  PubMed  Google Scholar 

  8. Cox JC, Coulter AR (1997) Adjuvants—a classification and review of their modes of action. Vaccine 15:248–256

    Article  PubMed  CAS  Google Scholar 

  9. Del Prete A, Vermi W, Dander E, Otero K, Barberis L, Luini W, Bernasconi S, Sironi M, Santoro A, Garlanda C, Facchetti F, Wymann MP, Vecchi A, Hirsch E, Mantovani A, Sozzani S (2004) Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. Embo J 23:3505–3515

    Article  PubMed  CAS  Google Scholar 

  10. Dennis EA (1994) Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 269:13057–13060

    PubMed  CAS  Google Scholar 

  11. Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59:221–226

    PubMed  CAS  Google Scholar 

  12. Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13:114–119

    Article  PubMed  CAS  Google Scholar 

  13. Gille H, Downward J (1999) Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 274:22033–22040

    Article  PubMed  CAS  Google Scholar 

  14. Grunebach F, Muller MR, Nencioni A, Brossart P (2003) Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 10:367–374

    Article  PubMed  CAS  Google Scholar 

  15. Grunebach F, Muller MR, Brossart P (2005) New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol Immunother 54:517–525

    Article  PubMed  CAS  Google Scholar 

  16. Höltl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M (1998) CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 352:1358

    Article  PubMed  Google Scholar 

  17. Höltl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777–782

    Article  PubMed  Google Scholar 

  18. Höltl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH, Thurnher M (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369–3376

    PubMed  Google Scholar 

  19. Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M (2004) Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54:663–670

    Article  PubMed  CAS  Google Scholar 

  20. Hsieh CC, Yen MH, Liu HW, Lau YT (2000) Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis 151:481–491

    Article  PubMed  CAS  Google Scholar 

  21. Johrer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, Ramoner R, Gander H, Holtl L, Bartsch G, Greil R, Thurnher M (2005) Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res 11:2459–2465

    Article  PubMed  Google Scholar 

  22. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11:701–713

    Article  PubMed  CAS  Google Scholar 

  23. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ (1979) Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 15:659–670

    PubMed  CAS  Google Scholar 

  24. Lechner JF, LaVeck MA (1985) A serum-free method for culturing normal human bronchial epithelial cells at clonal density. J Tissue Cult Methods 9:43–48

    Article  Google Scholar 

  25. Leitinger N (2003) Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 14:421–430

    Article  PubMed  CAS  Google Scholar 

  26. Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301–305

    Article  PubMed  CAS  Google Scholar 

  27. Mosior M, Six DA, Dennis EA (1998) Group IV cytosolic phospholipase A2 binds with high affinity and specificity to phosphatidylinositol 4,5-bisphosphate resulting in dramatic increases in activity. J Biol Chem 273:2184–2191

    Article  PubMed  CAS  Google Scholar 

  28. Murakami M, Kuwata H, Amakasu Y, Shimbara S, Nakatani Y, Atsumi G, Kudo I (1997) Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2. J Biol Chem 272:19891–19897

    Article  PubMed  CAS  Google Scholar 

  29. Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I (1997) Regulatory functions of phospholipase A2. Crit Rev Immunol 17:225–283

    PubMed  CAS  Google Scholar 

  30. Nakashima S, Ikeno Y, Yokoyama T, Kuwana M, Bolchi A, Ottonello S, Kitamoto K, Arioka M (2003) Secretory phospholipases A2 induce neurite outgrowth in PC12 cells. Biochem J 376:655–666

    Article  PubMed  CAS  Google Scholar 

  31. Nakashima S, Kitamoto K, Arioka M (2004) The catalytic activity, but not receptor binding, of sPLA(2)s plays a critical role for neurite outgrowth induction in PC12 cells. Brain Res 1015:207–211

    Article  PubMed  CAS  Google Scholar 

  32. Noseda A, White JG, Godwin PL, Jerome WG, Modest EJ (1989) Membrane damage in leukemic cells induced by ether and ester lipids: an electron microscopic study. Exp Mol Pathol 50:69–83

    Article  PubMed  CAS  Google Scholar 

  33. Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG (1994) Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. Arterioscler Thromb 14:1007–1013

    PubMed  CAS  Google Scholar 

  34. Payrastre B, Missy K, Giuriato S, Bodin S, Plantavid M, Gratacap M (2001) Phosphoinositides: key players in cell signalling, in time and space. Cell Signal 13:377–387

    Article  PubMed  CAS  Google Scholar 

  35. Perrin-Cocon L, Agaugue S, Coutant F, Masurel A, Bezzine S, Lambeau G, Andre P, Lotteau V (2004) Secretory phospholipase A2 induces dendritic cell maturation. Eur J Immunol 34:2293–2302

    Article  PubMed  CAS  Google Scholar 

  36. Putz T, Gander H, Ramoner R, Zelle-Rieser C, Rahm A, Nussbaumer W, Bartsch G, Höltl L, Thurnher M (2004) Generation of clinical grade monocyte-derived dendritic cells using the CliniMACS system. Methods Mol Med 24:653–663

    Google Scholar 

  37. Quinn MT, Parthasarathy S, Steinberg D (1988) Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 85:2805–2809

    Article  PubMed  CAS  Google Scholar 

  38. Ramoner R, Putz T, Gander H, Rahm A, Bartsch G, Schaber C, Thurnher M (2005) Dendritic cell activation by secretory phospholipase A2. Blood 105:3583–3587

    Article  PubMed  CAS  Google Scholar 

  39. Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M (1997) Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med 186:1603–1608

    Article  PubMed  CAS  Google Scholar 

  40. Rizzo MT, Nguyen E, Aldo-Benson M, Lambeau G (2000) Secreted phospholipase A(2) induces vascular endothelial cell migration. Blood 96:3809–3815

    PubMed  CAS  Google Scholar 

  41. Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ (2001) Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 49:415–419

    Article  PubMed  CAS  Google Scholar 

  42. Samadder P, Bittman R, Byun HS, Arthur G (2004) Synthesis and use of novel ether phospholipid enantiomers to probe the molecular basis of the antitumor Effects of alkyllysophospholipids: correlation of differential activation of c-Jun NH(2)-terminal protein kinase with antiproliferative effects in neuronal tumor cells. J Med Chem 47:2710–2713

    Article  PubMed  CAS  Google Scholar 

  43. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191:423–434

    Article  PubMed  CAS  Google Scholar 

  44. Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138–147

    Article  PubMed  CAS  Google Scholar 

  45. Six DA, Dennis EA (2000) The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 1488:1–19

    PubMed  CAS  Google Scholar 

  46. Stoll LL, Spector AA (1993) Lysophosphatidylcholine causes cGMP-dependent verapamil-sensitive Ca2+ influx in vascular smooth muscle cells. Am J Physiol 264:C885–C893

    PubMed  CAS  Google Scholar 

  47. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21:274–281

    Article  PubMed  CAS  Google Scholar 

  48. Toker A (2002) Phosphoinositides and signal transduction. Cell Mol Life Sci 59:761–779

    Article  PubMed  CAS  Google Scholar 

  49. Valentin E, Lambeau G (2000) What can venom phospholipases A(2) tell us about the functional diversity of mammalian secreted phospholipases A(2)? Biochimie 82:815–831

    Article  PubMed  CAS  Google Scholar 

  50. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD (2001) Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70:535–602

    Article  PubMed  CAS  Google Scholar 

  51. Weltzien HU, Richter G, Ferber E (1979) Detergent properties of water-soluble choline phosphatides. Selective solubilization of acyl-CoA:lysolecithin acyltransferase from thymocyte plasma membranes. J Biol Chem 254:3652–3657

    PubMed  CAS  Google Scholar 

  52. Wierecky J, Mueller M, Brossart P (2005) Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother (in press)

Download references

Acknowledgment

This work was supported by a grant to MT of the kompetenzzentrum medizin tirol (kmt), a center of excellence.

Author information

Authors and Affiliations

  1. Department of Urology, University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria

    Thomas Putz, Reinhold Ramoner, Hubert Gander, Andrea Rahm, Georg Bartsch & Martin Thurnher

Authors
  1. Thomas Putz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reinhold Ramoner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hubert Gander
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Rahm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Georg Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin Thurnher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Thurnher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Putz, T., Ramoner, R., Gander, H. et al. Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3,4)-bisphosphate. Cancer Immunol Immunother 55, 1374–1383 (2006). https://doi.org/10.1007/s00262-006-0143-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-006-0143-9

Keywords

Search

Navigation